Company intelligence / Profile preview

Onyx Pharmaceuticals

South San Francisco, California, United Statesonyxipca.com ↗

Ownership: Public · ONXX
Development stage: Commercial

Overview

Onyx developed and commercialized several oncology drugs. Sorafenib (Nexavar) was co-developed with Bayer for kidney and liver cancers. Carfilzomib (Kyprolis) was approved for relapsed/refractory multiple myeloma. Oprozomib and zetomipzomib were in clinical development at the time of acquisition. The company had a strong pipeline focused on proteasome inhibition and partnerships with major pharma companies like Bayer and Pfizer.

Therapeutic areas: OncologyHematology
Modalities: Small moleculessynthetic peptidesproteasome inhibitors
Industry: Biotech

Drug pipeline

3 assets

carfilzomib

Commercial

Indications: Multiple myeloma

2 more assets in the full pipeline.

Partnerships

Bayer AG – co-development/co-marketing of Nexavar/sorafenibPfizer – potential royalties on experimental breast cancer drug

Beyond the preview

Go deeper on Onyx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onyx Pharmaceuticals.